PEGASUS – TIMI 54 was a randomized, double-blind, placebo-controlled trial to assess the prevention of thrombotic events with ticagrelor on a background of aspirin therapy in patients with history of myocardial infarction.
MAIN RESULTS:
Long-term use of ticagrelor in patients with prior myocardial infarction

PRESENTATIONS
Main Results (Bonaca, ACC 2015)
Caffeine (AHA 2018, Furtado)
No PCI (AHA 2018, Furtardo)
hsTn (AHA 2018, Marston)
PEGASUS TMAO (Gencer AHA 2019)
A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients with Cardiometabolic Disease (Patel, AHA 2020)
PUBLICATIONS
No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials
Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54
Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54
Antithrombotic Therapy in Patients With Peripheral Artery Disease
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial